Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Chemical Society Reviews|February 8, 2012
Drug development: longer-lived proteinsStephan Kontos, Jeffrey A HubbellMolecular Pharmaceutics|September 14, 2010
Improving protein pharmacokinetics by engineering erythrocyte affinityStephan Kontos, Jeffrey A HubbellCurrent Opinion in Immunology|July 12, 2015
Engineering antigen-specific immunological toleranceStephan Kontos, Alizée J Grimm, Jeffrey A HubbellBiomaterials|September 25, 2010
Engineered aprotinin for improved stability of fibrin biomaterialsKristen M Lorentz, Stephan Kontos, Peter Frey, et al.Proceedings of the National Academy of Sciences of the United States of America|December 19, 2012
Engineering antigens for in situ erythrocyte binding induces T-cell deletionStephan Kontos, Iraklis C Kourtis, Karen Y Dane, et al.Science Advances|November 25, 2015
Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginaseKristen M Lorentz, Stephan Kontos, Giacomo Diaceri, et al.Molecular Cancer Therapeutics|November 9, 2014
Bicyclic peptides conjugated to an albumin-binding tag diffuse efficiently into solid tumorsLisa Pollaro, Sandeep Raghunathan, Julia Morales-Sanfrutos, et al.Scientific Reports|October 30, 2015
Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigensAlizée J Grimm, Stephan Kontos, Giacomo Diaceri, et al.Plos One|April 30, 2013
Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in miceIraklis C Kourtis, Sachiko Hirosue, Alexandre de Titta, et al.The Lancet. Gastroenterology & Hepatology|June 17, 2023
Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trialJoseph A Murray, Dina Wassaf, Karen Dunn, et al.Pageof 2